Search in:

Expert Opinion on Therapeutic Patents Volume 29, 2019 - Issue 3

Submit an article Journal homepage

Open access

6,909

Views

CrossRef citations to date

Altmetric

Review

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

Lukasz SkalniakDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Krakow, PolandCorrespondence[email protected]

https://orcid.org/0000-0002-6707-6697 View further author information

Ewa SurmiakDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Krakow, Poland

https://orcid.org/0000-0002-4103-4675 View further author information

Tad A. HolakDepartment of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Krakow, Poland

https://orcid.org/0000-0001-9369-6024 View further author information

Pages 151-170 | Received 10 Dec 2018, Accepted 11 Feb 2019, Published online: 01 Mar 2019

Cite this article
https://doi.org/10.1080/13543776.2019.1582645
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (24)

Jerson L. Silva, Debora Foguel, Vitor F. Ferreira, Tuane C. R. G. Vieira, Mayra A. Marques, Giulia D. S. Ferretti, Tiago F. Outeiro, Yraima Cordeiro & Guilherme A. P. de Oliveira. (2023) Targeting Biomolecular Condensation and Protein Aggregation against Cancer. Chemical Reviews 123:14, pages 9094-9138.
Crossref

Karolina I. Pellot Ortiz, Julian S. Rechberger, Leo F. Nonnenbroich, David J. Daniels & Jann N. Sarkaria. (2023) MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. Biomedicines 11:7, pages 1879.
Crossref

Jiahui Dong, Changlin Du, Chuanting Xu, Qi Wang, Zhonghao Wang, Qian Zhu, Xiongwen Lv, Lei Zhang, Jun Li, Cheng Huang, Hua Wang & Taotao Ma. (2023) Verbenalin attenuates hepatic damage and mitochondrial dysfunction in alcohol-associated steatohepatitis by regulating MDMX/PPARα-mediated ferroptosis. Journal of Ethnopharmacology 307, pages 116227.
Crossref

Nigar ÇARŞIBAŞI. (2023) Pharmacophore Modeling Guided by Conformational Dynamics Reveals Potent Anticancer AgentsKonformasyonel Dinamik Yönlendirmeli Farmakofor Modelleme ile Güçlü Antikanser Ajanlarının Belirlenmesi. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi 27:1, pages 51-63.
Crossref

Dominika Kowalczyk, Mark A Nakasone, Brian O Smith & Danny T Huang. (2022) Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function. Life Science Alliance 5:12, pages e202201472.
Crossref

Wei Zhao, Jiahui Yang, Xianghong Xie, Chunmei Li, Weihong Zhang, Enhui Chen, Yanfang Guo, Li Yan, Fude Fang, Hong Yao & Xiaojun Liu. (2022) A MDM2 inhibitor MX69 inhibits adipocytes adipogenesis and differentiation. Biochemical and Biophysical Research Communications 625, pages 9-15.
Crossref

Lan Luo, Xiaoyan Hu, Aoshuang Huang, Xiaofang Liu, Lingyun Wang, Tao Du, Lei Liu & Ming Li. (2022) A Noval Established Cuproptosis-Associated LncRNA Signature for Prognosis Prediction in Primary Hepatic Carcinoma. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-15.
Crossref

Hen Alali, Itai Bloch, Irena Rapaport, Luisa Rodrigues, Inbal Sher, Tamar Ansbacher & Maayan Gal. (2022) Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2. Pharmaceuticals 15:6, pages 752.
Crossref

Xueyun Huo, Wenjing Zhang, Guannan Zhao, Zhenwen Chen, Peixin Dong, Hidemichi Watari, Ramesh Narayanan, Todd D. Tillmanns, Lawrence M. Pfeffer & Junming Yue. (2022) FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways. Frontiers in Oncology 12.
Crossref

Meng Wu, Jingyi Cui, Huimin Hou, Ying Li, Shengjie Liu, Li Wan, Lili Zhang, Wei Huang, Gaoyuan Sun, Jingchao Liu, Pengfei Jin, Shunmin He & Ming Liu. (2022) Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer. Frontiers in Pharmacology 13.
Crossref

Matthias Baud. 2022. Spiro Compounds. Spiro Compounds 9 34 .

Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado & Funda Meric-Bernstam. (2021) First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research 23:1.
Crossref

Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu & Yujun Zhao. (2021) Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions. Journal of Medicinal Chemistry 64:15, pages 10621-10640.
Crossref

Xanthene Miles, Charlot Vandevoorde, Alistair Hunter & Julie Bolcaen. (2021) MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. Frontiers in Oncology 11.
Crossref

Francesca Mancini, Ludovica Giorgini, Emanuela Teveroni, Alfredo Pontecorvi & Fabiola Moretti. (2021) Role of Sex in the Therapeutic Targeting of p53 Circuitry. Frontiers in Oncology 11.
Crossref

Dehua Yu, Zhiyuan Xu, Xiangdong Cheng & Jiangjiang Qin. (2021) The role of miRNAs in MDMX‐p53 interplay. Journal of Evidence-Based Medicine 14:2, pages 152-160.
Crossref

Dmitry Namgaladze & Bernhard Brüne. (2021) Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists. Cancers 13:5, pages 958.
Crossref

Daniel Taillandier. (2021) Contrôle des voies métaboliques par les enzymes E3 ligases : une opportunité de ciblage thérapeutique. Biologie Aujourd’hui 215:1-2, pages 45-57.
Crossref

Dongxian Jiang, Lingli Chen, Jie Huang, Hao Wang, Qi Song, Peng Shi, Haixing Wang & Yingyong Hou. (2020) Mouse double minute 2 amplification in oesophageal squamous cell carcinoma is associated with better outcome . Histopathology 77:6, pages 963-973.
Crossref

Marina Konopleva, Giovanni Martinelli, Naval Daver, Cristina Papayannidis, Andrew Wei, Brian Higgins, Marion Ott, John Mascarenhas & Michael Andreeff. (2020) MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34:11, pages 2858-2874.
Crossref

De-Hua Yu, Zhi-Yuan Xu, Shaowei Mo, Li Yuan, Xiang-Dong Cheng & Jiang-Jiang Qin. (2020) Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges. Frontiers in Oncology 10.
Crossref

Bogdan Musielak, Weronika Janczyk, Ismael Rodriguez, Jacek Plewka, Dominik Sala, Katarzyna Magiera-Mularz & Tad Holak. (2020) Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions. Molecules 25:13, pages 3017.
Crossref

Margarida Espadinha, Stuart J. Conway & Maria M.M. Santos. 2020. Small Molecule Drug Discovery. Small Molecule Drug Discovery 267 288 .

Justyna Kocik, Monika Machula, Aneta Wisniewska, Ewa Surmiak, Tad A. Holak & Lukasz Skalniak. (2019) Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers 11:7, pages 1014.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

Articles from other publishers (24)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

Citations (24)

Articles from other publishers (24)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date